行情

VNRX

VNRX

VOLITIONRX
AMEX

实时行情|Nasdaq Last Sale

3.420
+0.070
+2.09%
已收盘, 16:00 04/07 EDT
开盘
3.490
昨收
3.350
最高
3.545
最低
3.350
成交量
8.53万
成交额
--
52周最高
6.84
52周最低
2.220
市值
1.40亿
市盈率(TTM)
-8.2046
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测VNRX价格均价为7.00,最高价位8.00,最低价为6.00。

EPS

VNRX 新闻

更多
  • Twitter创始人宣布捐献10亿美元抗击新冠病毒
  • 新浪科技 · 49分钟前
  • 特朗普:美国将研究暂扣为世卫组织提供的资金
  • 新浪美股 · 56分钟前
  • 隔夜要闻:道指回吐逾900点涨幅 美油下挫逾9%
  • 新浪美股 · 1小时前
  • 桥水达利欧:当印刷机不断印钞 仍认为现金就是垃圾
  • 新浪美股 · 1小时前

所属板块

医疗设备、用品及经销
-0.68%
医疗设备和用品
-0.82%

热门股票

代码
价格
涨跌幅

VNRX 简况

VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company's Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Company is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company's NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. It has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.
展开

微牛提供VolitionRX Ltd(AMEX-VNRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的VNRX股票新闻,以帮助您做出投资决策。